Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection
Brief Summary: A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undetectable hepatitis C virus \[HCV\] viral ribonucleic acid \[RNA\] at Week 4 in participants with chronic HCV infection. The primary hypothesis was that the proportion of participants in one or more of the Vaniprevir treatment groups achieving RVR would be greater than the proportion of placebo participants achieving RVR when Vaniprevir and placebo were co-administered with Peg-IFN/Ribavirin.


Options:
A: Arm Label: Immediate Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Arm Label: Deferred Treatment; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir, Drug: Placebo to Grazoprevir, Drug: Placebo to Elbasvir | Arm Label: Intensive PK; Type: EXPERIMENTAL; Interventions: Drug: Grazoprevir, Drug: Elbasvir | Intervention Type: DRUG; Name: Grazoprevir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Elbasvir; Assigned to Arm(s): Deferred Treatment, Immediate Treatment, Intensive PK | Intervention Type: DRUG; Name: Placebo to Grazoprevir; Assigned to Arm(s): Deferred Treatment | Intervention Type: DRUG; Name: Placebo to Elbasvir; Assigned to Arm(s): Deferred Treatment
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6
C: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435
D: Arm Label: Placebo + Peg-IFN/Ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin | Arm Label: Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Vaniprevir, Drug: Comparator: Pegylated-Interferon (Peg-IFN), Drug: Comparator: Ribavirin, Drug: Comparator: placebo | Intervention Type: DRUG; Name: Comparator: Vaniprevir; Assigned to Arm(s): Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Pegylated-Interferon (Peg-IFN); Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: Ribavirin; Assigned to Arm(s): Placebo + Peg-IFN/Ribavirin, Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin, Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin, Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin | Intervention Type: DRUG; Name: Comparator: placebo; Assigned to Arm(s): Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin

Answer: D